Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Rigel Pharmaceuticals, Inc. RIGL

Healthcare — Biotechnology
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
0.31
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — 1 — — 1 1 — — —
Insider Ownership
2.59%

Capital & Financial Ratios

Market Cap
856.47
Revenue
276.79
Net Income
321.91
Free Cash Flow
8.82
Net Debt
(95.33)
Current Ratio
1.94
Debt/Equity
0.00
P/E ratio
2.64
P/S ratio
3.12
P/B ratio
2.03
Past 5Y EPS Growth
19.96%
This Y EPS Growth
(82.39%)
Next Y EPS Growth
33.56%
Next 5Y EPS Growth
67.79%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 56.93 77.32 154.96 95.33
Receivables 30.55 41.62 51.76 56.04
Inventory 5.52 6.00 11.51 14.37
Other — — — —
99.27 135.10 240.17 185.53
2023 2024 2025 Q'26
Payables 7.14 3.34 7.19 4.01
ST’ Debt — — — —
Other 19.33 38.19 44.18 28.19
53.27 63.30 99.24 95.59
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 58.82 78.70 — —
—
’25 53.33 101.69 69.46 69.80
294.28
’24 29.53 36.84 55.31 57.60
179.28
’23 26.07 26.89 28.13 35.79
116.88
’22 16.74 29.82 22.41 51.28
120.24
’21 81.02 26.27 21.54 20.41
149.24
’20 55.76 16.02 18.39 18.45
108.62
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 2.73 30.65 — —
—
’25 (0.89) 30.54 24.03 21.98
75.66
’24 (5.01) 0.30 21.68 14.50
31.47
’23 (4.07) 5.93 (1.36) (6.24)
(5.74)
’22 (25.64) (12.91) (13.30) (21.91)
(73.76)
’21 (19.95) 55.22 (10.30) (19.09)
5.88
’20 (3.09) (14.04) (19.48) (15.57)
(52.18)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 2.73 (39.69) — —
—
’25 (0.89) 30.54 24.02 21.98
75.66
’24 (5.15) 0.08 21.70 14.55
31.17
’23 (18.95) 5.93 (1.34) (6.13)
(20.48)
’22 (25.86) (12.61) (13.21) (21.63)
(73.31)
’21 (20.03) 54.81 (10.47) (19.06)
5.25
’20 (3.70) (13.99) (19.68) (16.08)
(53.45)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.44 0.88 — —
—
’25 0.63 3.28 1.46 13.54
19.48
’24 (0.50) (0.06) 0.70 0.80
0.99
’23 (0.80) (0.40) (0.30) 0.00
(1.40)
’22 (1.60) (0.80) (1.10) 0.10
(3.40)
’21 2.20 (0.80) (1.20) (1.30)
(1.10)
’20 1.30 (1.00) (0.80) (1.10)
(1.80)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.8
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 6.40 7.10 7.48 15.50 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 35.20 20.40 29.82 52.24 — — —
High Price
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 155 147 164 174 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.78 0.80 1.09 1.69 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 120.24 116.88 179.28 294.28 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 98.55% 93.92% 89.60% 93.33% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (58.57) (25.09) 18.37 121.83 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (48.71%) (21.47%) 10.24% 41.40% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (58.57) (25.09) 17.49 367.02 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.94 0.76 1.52 1.27 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.05 6.72 10.20 16.36 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ (3.40) (1.40) 0.99 20.40 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.33) (0.33) 1.79 4.21 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.03 (0.85) (0.02) 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.30) (1.18) 1.77 4.21 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.80) (1.65) 0.19 21.76 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.05 17.40 17.58 17.99 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 17.52 2.12 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.90 2.17 1.65 2.62 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.00 89.93 1.97 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.75 2.14 1.51 2.17 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.88) (12.21) 8.67 8.46 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (73.76) (5.74) 31.47 75.66 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.44 (14.74) (0.30) — — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (73.31) (20.48) 31.17 75.66 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 50.69 46.00 71.80 140.93 — — —
Working Cap'
‡‡‡‡‡ — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 40.58 52.37 52.41 22.48 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.62) (4.56) (24.91) (132.47) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (13.62) (28.64) 3.29 391.48 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (38.84%) (19.95%) 12.44% 108.34% — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 30.28% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (699.05%) 118.75% (137.92%) 185.94% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Rigel Pharmaceuticals (RIGL), a clinical-stage biotech targeting immunology and hematology, has staged a notable turnaround with its flagship drug Tavalisse driving revenue from $20 million in 2016 to $179 million in 2024, alongside a shift to profitability—net income of $17.5 million and positive free cash flow in 2024 after years of deep losses. Operational efficiency shines through revenue per share up 372% and per employee surging 313%, with gross margins holding near 90%. Analyst forecasts fuel optimism: revenue projected to hit $293 million in 2025 (63% growth) and EPS leaping to $6.61, potentially delivering 20-30% annualized returns if executed.

Yet, this speculative opportunity carries classic biotech pitfalls, amplified by a fragile balance sheet—shareholders’ equity swung from negative $28.6 million in 2023 to a thin $3.3 million in 2024, with debt at $52 million despite ample cash. Historical cash burns, pipeline risks (90% failure rate), regulatory hurdles, and competition from giants like GlaxoSmithKline loom large, as does stock volatility (down 71% in 2022). Valuation looks cheap on forward multiples (5.2x PE), but negative book value history and lumpy capex demand caution—suitable only for small 2-3% allocations with tight stops. Dive into the full analysis for milestone watches and prudent positioning.

Read full commentary →

Rigel Pharmaceuticals, Inc. (RIGL) Latest News

News by impact score

Fine-tune

16 Aug

4 , 1:08 AM
Rigel Pharmaceuticals stock fair value lifts with Veppanu launch adding growth hope. Veppanu launch drives new growth for Rigel Pharmaceuticals.

13 Aug

4 , 8:05 AM
Rigel Pharmaceuticals announces availability of VEPPANU (vepdegestrant) for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer patients. New drug availability expands Rigel's oncology portfolio and revenue potential.

11 Aug

3 transcript www.fool.com, 8:46 PM
Rigel Pharmaceuticals held its Q2 2026 earnings call discussing financial results and company outlook. Earnings call details financial performance and outlook that may moderately affect near-term stock movement and operations.

5 Aug

3 transcript app.moby.co, 8:30 AM
Rigel Pharmaceuticals held its Q2 2026 earnings call, reporting financial results, operational updates, and forward-looking guidance for the company. Quarterly earnings calls deliver financial and strategic updates that moderately influence short-term sentiment and performance expectations.

4 Aug

3 transcript www.marketbeat.com, 10:03 PM
Rigel Pharmaceuticals Q2 earnings call covered financial results, product updates, pipeline progress and strategic outlook for RIGL operations and market positioning. Q2 earnings call updates financial performance and strategy with moderate influence on near-term investor sentiment and operations.

3 , 5:15 PM
Rigel Pharmaceuticals (RIGL) reported Q2 earnings that missed estimates. Q2 earnings miss may pressure near-term stock performance but does not signal fundamental changes to company trajectory.

3 , 4:01 PM
Rigel Pharmaceuticals reported its second quarter 2026 financial results. Quarterly financial results deliver performance data that can moderately shift market sentiment and valuation.

16 Jun

3 , 4:01 PM
Rigel Pharmaceuticals closed a licensing agreement for VEPPANU™ (vepdegestrant). Closing enables Rigel to advance VEPPANU commercialization and revenue potential.

23 May

3 Simply Wall St., 10:08 PM
Pfizer oncology partnerships intensify valuation and earnings concerns for Rigel Pharmaceuticals. Pfizer partnerships highlight ongoing valuation and earnings pressures for Rigel.

21 May

4 Simply Wall St., 1:12 AM
Pfizer secured a VEPPANU license from Rigel Pharmaceuticals, creating a fresh strategic element in Pfizer's portfolio and positioning Rigel for potential revenue and partnership gains. VEPPANU licensing deal with Pfizer delivers major revenue potential and strategic validation for Rigel.

15 May

4 Benzinga, 4:31 PM
Rigel Pharmaceuticals partners with Arvinas and Pfizer on breast cancer drug development. Deal with Arvinas and Pfizer marks major strategic move into oncology with potential to shift Rigel trajectory.

14 May

4 Simply Wall St., 2:13 AM
Rigel Pharmaceuticals (RIGL) shares surged 20.5% after securing global rights to VEPPANU through a deal with Pfizer and Arvinas, prompting analysis on whether this strengthens the bull case. Global VEPPANU rights deal with Pfizer and Arvinas drives 20.5% stock surge and bolsters RIGL's pipeline via major strategic partnership.

13 May

4 Simply Wall St., 4:17 AM
Pfizer shifts rights to VEPPANU to Rigel Pharmaceuticals amid persisting valuation gap between the companies. Pfizer transferring VEPPANU rights provides Rigel with a major pipeline asset, likely boosting its strategic position and investor sentiment.

12 May

4 www.biopharmadive.com, 8:05 AM
Arvinas and Pfizer have selected Rigel Pharmaceuticals, Inc. (RIGL) as their new partner for the Protac breast cancer drug. Rigel secures partnership with Arvinas and Pfizer on Protac breast cancer drug, enabling major pipeline expansion and revenue potential.

4 GlobeNewswire, 7:00 AM
Arvinas and Pfizer entered a transaction with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (vepdegestrant). Transaction with Arvinas and Pfizer for exclusive global rights to VEPPANU represents a major strategic partnership likely boosting Rigel's revenue and market position.

4 PR Newswire, 7:00 AM
Rigel Pharmaceuticals enters exclusive global licensing agreement for VEPPANU™ (vepdegestrant), an oral PROTAC targeting 2L+ ER+/HER2-, ESR1m advanced or metastatic breast cancer. Exclusive global licensing of a novel oral PROTAC for ESR1-mutated breast cancer significantly expands Rigel's oncology pipeline and potential revenue streams.

3 Simply Wall St., 8:58 AM
Analysts argue Rigel Pharmaceuticals' (NASDAQ:RIGL) earnings poorly indicate its profitability, suggesting investors should look beyond reported figures for true financial health. Questioning earnings reliability impacts perceptions of financial performance and investor sentiment without fundamentally altering core operations.

6 May

4 app.moby.co, 8:30 AM
Rigel Pharmaceuticals, Inc. released Q1 2026 earnings call summary detailing quarterly financial results, operational updates, and forward guidance. Quarterly earnings summaries disclose revenues, expenses, pipeline progress, and outlook, significantly swaying investor sentiment and stock trajectory.

5 May

4 PR Newswire, 4:01 PM
Rigel Pharmaceuticals, Inc. (RIGL) reported first quarter 2026 financial results. Quarterly earnings reports reveal financial health and performance metrics that significantly influence stock price and investor sentiment.

3 www.marketbeat.com, 10:07 PM
Rigel Pharmaceuticals reported Q1 2024 net product sales of $28.0 million, up 11% year-over-year, with Tavalisse at $27.6 million and Rezlidhia at $1.3 million. Cash position stood at $75.4 million. Pipeline updates included R289 Phase 1 data, planned Phase 3 for RIPK1 inhibitor, and fosamprenavir NDA submission targeted for H2 2024. Q1 revenue growth and pipeline progress provide moderate boost to financials and outlook amid cash constraints.

3 Zacks, 6:05 PM
Rigel Pharmaceuticals (RIGL) reported Q1 earnings and revenue below analyst estimates. Missing Q1 earnings and revenue estimates highlights weaker-than-expected financial performance, likely causing moderate short-term pressure on stock price and investor sentiment.

28 Apr

3 Zacks, 10:00 AM
Rigel Pharmaceuticals (RIGL) will report Q1 results as Wall Street anticipates earnings growth. Upcoming Q1 earnings report with expected growth could moderately impact financial performance and investor sentiment.

31 Mar

3 PR Newswire, 8:05 AM
Rigel Pharmaceuticals announced publication of final ARROW trial data on GAVRETO (pralsetinib) showing durable responses in RET fusion-positive NSCLC patients in the Journal of Clinical Oncology. Publication of final trial data in a prestigious journal validates GAVRETO's efficacy, potentially enhancing Rigel's revenue from commercialization rights and investor sentiment.

4 Mar

4 GuruFocus.com, 12:02 AM
Rigel Pharmaceuticals (RIGL) reported record net income in Q4 2025 earnings call, highlighting key financial achievements and future growth prospects. Record net income marks a major financial milestone that could significantly boost investor sentiment and stock performance.

3 Mar

4 Simply Wall St., 9:11 PM
Rigel Pharmaceuticals (RIGL) evolves its investment narrative amid new therapeutic targets and advancing drug pipeline. New targets and pipeline progress indicate major strategic advancements likely to boost RIGL's competitive position and market performance.

4 www.marketbeat.com, 6:02 PM
Rigel Pharmaceuticals released highlights from its Q4 earnings call, covering financial results, pipeline progress, and forward guidance. Q4 earnings highlights detail financial performance, operational updates, and strategic outlook, poised to significantly sway investor sentiment and stock trajectory.

3 transcript www.fool.com, 6:07 PM
Rigel Pharmaceuticals (RIGL) earnings call transcript details quarterly financial results, pipeline updates, and forward-looking statements on operations and growth strategies. Earnings calls reveal financial metrics, guidance, and pipeline progress that moderately influence stock performance and investor sentiment.

3 Zacks, 5:15 PM
Rigel Pharmaceuticals (RIGL) reported Q4 earnings that missed analyst estimates. Q4 earnings miss affects financial performance and investor sentiment moderately but is balanced by other operational factors.

3 Associated Press Finance, 4:18 PM
Rigel Pharmaceuticals, Inc. (RIGL) released Q4 earnings snapshot highlighting financial results. Q4 earnings snapshots provide key financial insights that moderately affect Rigel's performance and investor sentiment.

3 PR Newswire, 4:01 PM
Rigel Pharmaceuticals reported fourth quarter and full-year 2025 financial results alongside a business update. Quarterly and annual financial disclosures with business updates typically exert moderate influence on stock performance and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us